| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A portion of amino acids 1478-1506 from the human protein was used as the immunogen for the TIAM1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
TIAM1 Antibody / T cell lymphoma invasion and metastasis 1 is an antibody targeting TIAM1, raised in Rabbit for protein detection and localization studies where these specifications are required.
Key elements and design rationale
- Target: TIAM1.
- Antibody identity: Polyclonal (rabbit origin); Rabbit Ig.
- Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
- Format: Purified.
- Species reactivity: Human.
- Listed applications: WB (refer to on-page specifications for application-specific guidance).
Biological background
TIAM1 is a protein that plays a crucial role in cell migration and invasion. In T cell lymphoma, increased expression of TIAM1 has been associated with enhanced invasive capabilities of cancer cells. TIAM1 promotes the formation of invasive structures called invadopodia, which facilitate cancer cell movement through tissues. Additionally, TIAM1 has been shown to activate signaling pathways that promote metastasis, making it a key player in the spread of T cell lymphoma. Studies have demonstrated that targeting TIAM1 can inhibit T cell lymphoma invasion. By disrupting the activity of TIAM1, researchers have been able to reduce the ability of cancer cells to invade surrounding tissues. This suggests that TIAM1 could be a potential therapeutic target for inhibiting T cell lymphoma invasion and slowing down disease progression. Metastasis is a major concern in T cell lymphoma, as cancer cells can spread to distant organs and tissues, leading to poor prognosis. TIAM1 has been implicated in promoting the metastatic spread of T cell lymphoma cells. By targeting TIAM1, researchers have observed a decrease in the ability of cancer cells to metastasize, highlighting the potential of TIAM1 as a therapeutic target for preventing T cell lymphoma metastasis.
Research relevance and current trends
- Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
- Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
- Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.
Common research applications
- Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.
Notes for experimental interpretation
- Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
- Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
- Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
- Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
